Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2021 - 2025)
Zentalis Pharmaceuticals' quarterly Asset Writedowns and Impairment came in at $3.0 million in Q4 2025, up 159.03% quarter-over-quarter from $1.2 million in Q1 2025.
Zentalis Pharmaceuticals has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $3.0 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 159.03% YoY), and the FY2025 full-year result was $4.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $3.0 million, up from $1.2 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $5.0 million in Q1 2023, with the low at -$8.8 million in Q4 2021.
- Average Asset Writedowns and Impairment over 3 years is $72250.0, with a median of $2.1 million recorded in 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2023 | 4.95 Mn |
| Mar 31, 2023 | 4.95 Mn |
| Dec 31, 2021 | -8.80 Mn |
| Dec 31, 2021 | -8.80 Mn |